SCM
SLNO

Suvretta Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Suvretta Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-383,880
Closed -$11.1M – 127
2020
Q4 		$11.1M Buy
383,880
+168,763
+78% +$4.87M 0.16% 60
2020
Q3 		$8.1M Buy
215,117
+46,625
+28% +$1.36M 0.15% 56
2020
Q2 		$5.61M Buy
+168,492
New +$7.3M 0.12% 55

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Suvretta Capital Management's SLNO Position: Q1 2021 in Review

Suvretta Capital Management sold out of Soleno Therapeutics (SLNO) in Q1 2021, closing a stake of 383,880 shares — an estimated $11.1M sold.

Suvretta Capital Management first reported a position in SLNO in Q2 2020 and held it in 3 quarters. The position peaked at $11.1M in Q4 2020. 63 funds tracked by Wall St. Rank hold SLNO as of Q1 2021.

  • Suvretta Capital Management reported no remaining Soleno Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Suvretta Capital Management sold 383,880 Soleno Therapeutics shares in Q1 2021, an estimated $11.1M.
  • Suvretta Capital Management first reported a position in Soleno Therapeutics in Q2 2020 and held it in 3 quarters.
  • Suvretta Capital Management's Soleno Therapeutics position peaked at $11.1M in Q4 2020.
  • 63 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2021.

Based on Suvretta Capital Management's 13F filing for Q1 2021, filed 17 May 2021.